• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Athira Pharma Inc (NQ: ATHA )

    0.4281 -0.0210 (-4.68%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Athira Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
    From Athira Pharma, Inc.
    Via GlobeNewswire
    NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
    San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA). 
    Via SBWire
    Athira Outlines Possible Comeback For Alzheimer's Candidate
    Via Benzinga
    Athira Pharma: Q2 Earnings Insights
      Athira Pharma (NASDAQ:ATHA) reported its Q2 earnings results on Monday, August 15, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    4 Analysts Have This to Say About Athira Pharma
    Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: 
    Via Benzinga
    Athira Pharma Provides 2023 Pipeline Outlook
    From Athira Pharma, Inc.
    Via GlobeNewswire
    4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
    US stocks recorded losses for 2022. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's... 
    Via Benzinga
    Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
    Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
    The Dow Jones closed lower by nearly 350 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
    Via Benzinga
    Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
    Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
    HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
    Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Around $4 Million Bet On Lesaka Technologies? Check Out These 4 Penny Stocks Insiders Are Buying
    US crude oil futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
    Via Benzinga
    Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present at Stifel 2022 Healthcare Conference
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
    Data supports neuroprotective and disease modifying potential in models of Parkinson’s disease and diabetic neuropathy 
    From Athira Pharma, Inc.
    Via GlobeNewswire
    Athira Pharma Advances Phase 2/3 LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients Following Independent, Unblinded Interim Analysis
    From Athira Pharma, Inc.
    Via GlobeNewswire
    The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022
    Upgrades 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
    Upgrades 
    Via Benzinga
    10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More
    Morgan Stanley cut Westinghouse Air Brake Technologies Corporation (NYSE: WAB) price target from $113 to $94. Westinghouse Air Brake Technologies shares fell 1.7% to $82.36 in pre-market trading. 
    Via Benzinga
    76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
    Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
    Via Benzinga
    Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher
    U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Wednesday. 
    Via Benzinga
    Stocks Quietly Higher as Market Attempts to Extend Rally
    Stocks are modestly higher at midday. 
    Via Talk Markets
    U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
    U.S. stocks turned higher midway through trading, with the Nasdaq Composite gaining around 30 points on Wednesday. 
    Via Benzinga
    40 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares jumped 116.6% to $12.82 after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.